Mac1 ADP-ribosylhydrolase是SARS-CoV-2的治疗标之一
Rahul K Suryawanshi1, Priyadarshini Jaishankar2, Galen J Correy3
1Gladstone Institute of Virology, Gladstone Institutes, San Francisco, United States.
eLife
|November 19, 2025
概括
一种名为AVI-4206的新药针对SARS-CoV-2的Mac1酶恢复免疫反应. 这种方法对治疗COVID-19和开发更广泛的抗病毒疗法充满希望.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 药物发现 药物发现 药物发现
背景情况:
- 严重急性呼吸道综合征冠状病毒2 (SARS-CoV-2) 构成严重的公共卫生风险.
- 现有的SARS-CoV-2治疗方法有限,并面临病毒抵抗.
- 通过抑制宿主免疫力,SARS-CoV-2 Mac1酶对病毒复制至关重要.
研究的目的:
- 为了研究药理上抑制SARS-CoV-2 Mac1酶的治疗潜力.
- 评估一种新型小分子抑制剂AVI-4206的抗病毒功效.
- 探索一种新的免疫恢复机制,用于抗病毒药物开发.
主要方法:
- 利用细胞模型,人类呼吸道器官和外围血液单细胞衍生的巨细胞来评估AVI-4206.
- 在已建立的严重SARS-CoV-2感染动物模型中测试AVI-4206.
- 评估了目标参与,病毒复制抑制,宿主天生的免疫反应强化和生存益处.
主要成果:
- 在标准细胞模型中,AVI-4206表现出高目标参与度和弱抑制.
- 在人类呼吸道器官和巨细胞中观察到AVI-4206更明显的抗病毒作用.
- 在体内,AVI-4206降低了病毒载量,增强了先天免疫力,并在SARS-CoV-2感染模型中改善了生存率.
结论:
- 对SARS-CoV-2 Mac1的药理抑制是一种可行的治疗策略.
- AVI-4206代表了通过免疫恢复准病毒Mac1的概念验证.
- 这种方法可能与现有疗法提供协同效益,并适用于其他病毒宏观主体.
相关概念视频
02:47Ribozymes
13.2K
The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can...
Ribozymes can...
13.2K
02:28Leaky Scanning
5.6K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.6K